NCT02612194

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm two-stage phase II study with crizotinib (Xalkori®) in the treatment of subjects with metastatic urothelial cancer of the bladder, upper (ureter or renal pelvis) or lower (urethra) urinary tracts. The purpose of this study is to see if this experimental drug has a potential benefit in subjects with stage 4 urothelial cancer. This study tests crizotinib used alone in subjects with urothelial cancer, previously treated with chemotherapy, and whose tumors have certain proteins. Proteins are complex natural substances essential to the structure and function of all living cells. These proteins, c-MET or RON, may trigger molecular pathways that are involved in the growth and spread of bladder or upper urinary tract cancer. Crizotinib is a drug taken by mouth that blocks these pathways. Early laboratory research suggests that crizotinib may benefit patients with urothelial and other cancers with these molecular pathways.

Detailed description

This is a single arm two-stage phase II study designed to evaluate the objective response rate in subjects with metastatic urothelial cancer demonstrating c-MET or RON overexpression who have received prior therapy with a cisplatin or carboplatin containing regimen. Subjects will be recruited at Levine Cancer Institute (LCI) and other participating sites. Immunohistochemistry will be utilized to define tumor sample c-MET and RON protein expression patterns for assignment into molecular cohorts as described in section 12.1. In the first stage of this study, subjects will be enrolled in parallel to three molecularly defined cohorts as follows: 1. c-MET high (\>50%), RON null (0-9%) (n = 14 subjects) 2. c-MET-positive (10-100%), RON-positive (10-100%) (n = 7 subjects) 3. c-MET null (0-9%), RON-positive (10-100%) (n = 7 subjects) All enrolled subjects will continue with study treatment until criteria for treatment discontinuation has been met. If Stage 1 response criteria are met in a cohort, the cohort may be considered for expansion, and additional subjects (16 in Cohort 1 or 25 in Cohorts 2 or 3) may then be enrolled into that cohort in Stage 2. An expansion cohort will be defined by the Sponsor- Investigator following review of all available trial data which will be conducted after the first Stage 1 cohort has completed accrual and at least every six months thereafter until all Stage 1 cohorts have completed accrual. If more than one cohort meets Stage 1 response criteria (2 responses out of 14 subjects for Cohort 1 or 1 response out of 7 subjects for each of Cohorts 2 and 3), then the cohort showing the highest response rate will be given highest consideration for expansion.

Conditions

• Urinary Bladder Neoplasms
• Ureteral Neoplasms
• Urethral Neoplasms

Interventions

Type	Name	Description
DRUG	Crizotinib	Crizotinib was administered orally at 250mg twice daily

Timeline

• Start date: 2016-09-27
• Primary completion: 2019-09-17
• Completion: 2019-11-21
• First posted: 2015-11-23
• Last updated: 2022-11-03
• Results posted: 2021-06-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study